Is Krishna Institute of Medical Sciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Krishna Institute of Medical Sciences Ltd is a good quality company .

Is Krishna Institute of Medical Sciences undervalued or overvalued?

The key valuation ratios of Krishna Institute of Medical Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Krishna Institute of Medical Sciences share price return in the past 10 years?

Data is not available for this company

Is Krishna Institute of Medical Sciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Krishna Institute of Medical Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Krishna Institute of Medical Sciences?

The latest standalone P/E ratio of Krishna Institute of Medical Sciences as of 19-Apr-2024 is 59.51.

What is the P/B ratio of Krishna Institute of Medical Sciences?

The latest standalone P/B ratio of Krishna Institute of Medical Sciences as of 19-Apr-2024 is 8.57.

What is the 52-week high and low of Krishna Institute of Medical Sciences?

The 52-week high of Krishna Institute of Medical Sciences is Rs. 2357.00 and the 52-week low is Rs. 1452.60.

What is the TTM revenue of Krishna Institute of Medical Sciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Krishna Institute of Medical Sciences is Rs. 1210.56 (Cr.).

Krishna Institute of Medical Sciences Ltd - Stock Valuation and Financial Performance

Name: Krishna Institute of Medical Sciences
Brand: Krishna Institute of Medical Sciences

BSE: 543308 | NSE: KIMS | Hospital & Healthcare Services | Small Cap

Place order

Krishna Inst.Medi Share Price

₹1,970 20.65 1.06%
as on 19-Apr'24 16:01

10 Year X-Ray of Krishna Inst.Medi:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	6.3%	6.3%	9.7%	-3.3%	-4.1%	-3.2%	18.4%	21.9%	23.6%	16.9%	-
Value Creation Index ⓘ	-0.5	-0.5	-0.3	NA	NA	-1.2	0.4	0.6	0.8	0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	349	394	485	536	628	707	790	933	1,143	1,132	1,211
Sales YoY Gr.	-	12.7%	23.1%	10.5%	17.3%	12.5%	11.8%	18.1%	22.6%	-1%	-
Adj EPS ⓘ	1	1	3.4	-14.4	-16.2	-5.9	16.3	24.4	35	31.6	32.7
YoY Gr.	-	-4.9%	254.6%	-517.4%	NA	NA	NA	49.8%	43.4%	-9.9%	-
BVPS (₹) ⓘ	29.1	33.6	37.1	-23.9	-39.7	67.6	83.8	116.9	172.1	203.8	227.2
Adj Net Profit ⓘ	6.9	6.9	24.3	-72	-81.3	-43.6	121	189	280	253	262
Cash Flow from Ops. ⓘ	79.8	56.7	89.4	79.7	94.2	109	161	291	284	270	-
Debt/CF from Ops. ⓘ	3.3	4.9	2.8	7.9	7.1	1.7	1.1	0.4	0.1	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	14%	12.5%	12.7%	-1%
Adj EPS ⓘ	46.4%	NA	24.6%	-9.9%
BVPSⓘ	24.1%	NA	34.5%	18.4%
Share Price	-	-	-	30.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	3.6	3.2	9.7	-101.9	51	-28.6	21.5	24.7	24.5	16.8	15.2
Op. Profit Mgn % ⓘ	19.2	18.9	21.6	10.4	10.3	8.1	26.1	33.1	35	32.1	31.6
Net Profit Mgn % ⓘ	2	1.7	5	-13.4	-12.9	-6.2	15.4	20.3	24.5	22.3	21.6
Debt to Equity ⓘ	1.4	1.2	1	-5.2	-3.3	0.4	0.3	0.1	0	0	-
Working Cap Days ⓘ	80	89	86	91	92	97	88	66	64	90	36
Cash Conv. Cycle ⓘ	-20	39	-13	-26	4	8	-11	-6	-7	3	17

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 12.74%

Net Profit is growing at healthy rate in last 3 years 24.64%

Sales growth is good in last 4 quarters at 10.93%

Return on Equity has declined versus last 3 years average to 15.20%

Latest Financials - Krishna Institute of Medical Sciences Ltd

	Standalone	Consolidated
TTM EPS (₹)	32.7	42.2
TTM Sales (₹ Cr.)	1,211	2,440
BVPS (₹.) ⓘ	227.2	236.2
Reserves (₹ Cr.) ⓘ	1,738	1,810
P/BV ⓘ	8.57	8.25
PE ⓘ	59.51	46.11

From the Market
52 Week Low / High (₹)	1452.60 / 2357.00
All Time Low / High (₹)	938.05 / 2357.00
Market Cap (₹ Cr.)	15,583
Equity (₹ Cr.)	80
Face Value (₹)	10
Industry PE ⓘ	84.1

Management X-Ray of Krishna Inst.Medi:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

13.45

14.86

15.74

19.39

18.10

15.53

16.16

16.10

* Pledged shares as % of Promoter's holding (%)

Valuation of Krishna Inst.Medi

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Krishna Inst.Medi

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	349	394	485	536	628	707	790	933	1,143	1,132
Operating Expenses ⓘ	284	321	380	480	564	650	584	625	745	769
Manufacturing Costs	109	131	154	41	198	203	49	243	281	287
Material Costs	99	104	119	130	152	167	180	201	250	238
Employee Cost	55	66	76	92	115	127	137	147	174	187
Other Costs ⓘ	21	21	31	217	99	154	218	34	40	57
Operating Profit ⓘ	65	73	105	56	65	57	206	308	398	363
Operating Profit Margin (%)	18.6%	18.6%	21.6%	10.4%	10.3%	8.1%	26.1%	33.0%	34.8%	32.1%
Other Income ⓘ	6	4	4	3	4	6	7	10	27	24
Interest ⓘ	31	34	36	79	88	36	24	18	9	5
Depreciation ⓘ	25	31	34	35	38	41	43	45	45	45
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	15	12	38	-55	-57	-13	147	254	371	337
Tax ⓘ	10	6	14	17	24	30	25	66	93	85
Profit After Tax	5	6	24	-72	-81	-44	121	189	278	252
PAT Margin (%)	1.5%	1.5%	5.0%	-13.4%	-12.9%	-6.2%	15.3%	20.2%	24.3%	22.3%
Adjusted EPS (₹)	0.8	0.8	3.5	-14.4	-16.2	-5.9	16.3	24.3	34.8	31.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	196	237	261	-120	-199	504	624	907	1,378	1,631
Share Capital ⓘ	6	9	70	50	50	74	74	78	80	80
Reserves ⓘ	190	228	191	-170	-249	429	549	830	1,298	1,551
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	226	229	188	208	241	161	149	118	4	0
Long Term Debt	200	198	173	198	214	152	147	68	4	0
Short Term Debt	26	32	15	10	27	9	2	50	0	0
Trade Payables	57	58	63	74	79	74	78	85	81	73
Others Liabilities ⓘ	138	114	134	581	669	119	106	103	106	108
Total Liabilities ⓘ	618	638	646	743	789	857	957	1,214	1,569	1,812
Fixed Assets
Gross Block	552	624	657	539	648	680	712	775	827	889
Accumulated Depreciation	102	130	159	35	72	113	153	193	235	277
Net Fixed Assetsⓘ	450	494	498	504	576	567	559	582	592	612
CWIP ⓘ	51	10	2	64	0	0	2	8	13	16
Investmentsⓘ	6	15	18	23	31	80	178	213	542	826
Inventories	10	10	11	15	16	19	22	16	26	19
Trade Receivables	30	35	62	76	96	100	99	73	87	120
Cash Equivalents	25	13	7	8	9	8	39	250	180	40
Others Assetsⓘ	46	61	48	53	61	83	58	71	128	178
Total Assets ⓘ	618	638	646	743	789	857	957	1,214	1,569	1,812

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	80	57	89	80	94	109	161	291	284	270
PBT ⓘ	14	12	38	-55	-57	-13	147	254	371	337
Adjustment ⓘ	56	65	69	172	188	177	62	55	26	24
Changes in Working Capital ⓘ	21	-8	-19	-26	-16	-29	-1	25	-17	-17
Tax Paid ⓘ	-11	-12	1	-11	-22	-25	-47	-43	-96	-75
Cash Flow From Investing Activity ⓘ	-68	-64	-39	-100	-52	-99	-108	-317	-375	-237
Capex	-55	-72	-33	-100	-45	-46	-21	-72	-69	-121
Net Investments	-10	16	-3	0	0	0	0	-212	56	119
Others ⓘ	-3	-8	-3	0	-7	-53	-87	-33	-362	-235
Cash Flow From Financing Activityⓘ	-10	11	-61	25	-42	-12	-24	25	76	-15
Net Proceeds from Shares ⓘ	0	37	0	31	0	88	0	95	192	0
Net Proceeds from Borrowing ⓘ	0	0	0	89	-29	-143	-35	-102	-60	-14
Interest Paid ⓘ	-32	-35	-34	-31	-28	-21	-19	-14	-4	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	23	9	-26	-63	16	63	30	46	-51	0
Net Cash Flow ⓘ	2	4	-10	5	0	-2	28	0	-15	18

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	2.8	2.68	9.76	N/A	N/A	-28.67	21.48	24.64	24.37	16.79
ROCE (%)	10.26	9.46	14.56	N/A	N/A	3.9	22.72	29.57	31.24	22.58
Asset Turnover Ratio	0.59	0.63	0.75	0.77	0.82	0.86	0.87	0.86	0.82	0.67
PAT to CFO Conversion(x)	16	9.5	3.71	N/A	N/A	N/A	1.33	1.54	1.02	1.07
Working Capital Days
Receivable Days	30	30	36	47	50	51	46	34	26	33
Inventory Days	9	9	8	9	9	9	9	7	7	7
Payable Days	176	203	186	191	183	167	154	148	121	118

Krishna Institute of Medical Sciences Ltd Stock News

Krishna Institute of Medical Sciences Ltd FAQs

What is the share price of Krishna Inst.Medi?

Company share prices are keep on changing according to the market conditions. The closing price of Krishna Inst.Medi on 19-Apr-2024 16:01 is ₹1,970.

What is the market cap of Krishna Inst.Medi?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Apr-2024 16:01 the market cap of Krishna Inst.Medi stood at ₹15,582.6.

What is the P/E ratio of Krishna Inst.Medi?

The latest P/E ratio of Krishna Inst.Medi as of 19-Apr-2024 16:01 is 59.51.

What is the P/B ratio of Krishna Inst.Medi?

The latest P/B ratio of Krishna Inst.Medi as of 19-Apr-2024 16:01 is 8.57.

What is the 52-week high and low of Krishna Inst.Medi?

The 52-week high of Krishna Inst.Medi is ₹2,357 and the 52-week low is ₹1,452.6.

What is the TTM revenue of Krishna Inst.Medi?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Krishna Inst.Medi is ₹1,211 ( Cr.) .

About Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences is one of the largest corporate healthcare groups in AP and Telangana in terms of number of patients treated and treatments offered. It also provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care in Tier 2-3 cities and primary, secondary, tertiary and quaternary healthcare in Tier 1 cities. It operates multi-specialty hospitals under the “KIMS Hospitals” brand. It also offers a comprehensive range of healthcare services across specialties and super specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother & child care.

The company strives to provide quality service to more patients, and it has scope for additional patients and improved occupancy rates. It strategically focuses on the southern India healthcare market where it has a strong understanding of regional nuances, customer culture and the mindset of medical professionals and where there is significant and growing need for quality and affordable healthcare services. Each of its hospitals also has integrated diagnostic services and pharmacies that cater to its patients. Affordability and quality of healthcare services provided by it and its track record of building long-term relationships with medical professionals including its doctors, has enabled growth and helped it build its ‘KIMS Hospitals’ brand. It operates and manages all of its hospitals, which provides it with greater control over its facilities and helps it to better deliver high quality and affordable healthcare services.

Business area of the company

The company offers a comprehensive range of healthcare services including oncology, cardiac sciences, neurosciences, gastric sciences, orthopaedics, renal sciences, organ transplantation, and mother & child care.

Awards and Accreditations

2008: KIMS Secunderabad received its first ISO 9001-2008 certification from AQA International LLC.
2011: KIMS Secunderabad received its first accreditation from NABH.
2015: KIMS Secunderabad was awarded the ‘Healthcare Excellence Award’ by the Indo Global Healthcare Summit and Expo.
2015: KIMS Secunderabad was awarded ‘Nursing Excellence’ award by AHPI.
2015: KIMS Secunderabad was accredited with ISO 9001:2015 certification.
2017: KIMS Secunderabad was awarded by AHPI as a ‘Patient Friendly Hospital’.
2017: KIMS Secunderabad became laureate of the Asia Pacific Society of Infection Control CSSD Center of Excellence Silver Award 2015-2016.
2017: KIMS Secunderabad was awarded ‘Best Hospital of the Year’ in the multispecialty hospital category in Hyderabad and eight other specialities by Times Healthcare Achievers Awards.
2019: 2019 KIMS Secunderabad received certificate of excellence in the category of ‘Best Super-Speciality Hospital in Telangana’ at the National Quality Excellence Awards, 2019 hosted by Praxis Media Institute.
2019: KIMS Secunderabad was awarded ‘Best Hospital to Work For’ from AHPI Global Conclave.
2019: KIMS Secunderabad was accredited by NABL.
2019: KIMS Nellore was issued a certificate of accreditation by NABH for being compliant with NABH pre-accreditation entry level hospital requirements.
2020: KIMS Secunderabad ranked the third best hospital in Hyderabad by The Week magazine.
2020: KIMS Kondapur was accredited with a certificate of assessment for exhibition of its intent and commitment towards ensuring safety and hygiene at workplace by IRClass Systems and Solutions.
2021: The cardiology, emergency and trauma, nephrology and neuroscience departments of KIMS Hyderabad were ranked first in the Hyderabad Multi Speciality category in the Times of India, Hyderabad, All India Critical Care Hospital Ranking Survey, 2021.
2021: The emergency and trauma and nephrology departments of KIMS Hyderabad were ranked second in the South Multi Speciality Category in the Times of India, Hyderabad, All India Critical Care Hospital Ranking Survey, 2021.

Major events and milestones

2000: KIMS Nellore established by BRMH. The business division of BRMH, including the hospital, was transferred to our Company pursuant to the 2012 Scheme.
2004: KIMS Secunderabad established by Company.
2010: Investment by Milestone Private Equity Fund (“MPEF”) in Company.
2014: Acquisition of 57.83% of the equity shareholding of Arunodaya Hospitals.
2015: Investment by India Advantage Fund (IAF) and Emerging India Fund (EIF) and exit of MPEF from our Company pursuant to the share purchase agreement dated June 23, 2014 entered into between, amongst others, IAF, EIF and MPEF.
2017: Acquisition of KIMS Ongole by way of slump sale agreement.
2019: Acquisition of 51% of the equity shareholding of ICIMSPL.
2019: Acquisition of 80% of the equity shareholding of SIMSPL.
2019: Investment by General Atlantic in our Company and exit of IAF and EIF from our Company pursuant to the share purchase agreement dated June 14, 2018 entered into between, amongst others, General Atlantic, IAF and EIF.
2020: Acquisition of 55% of the equity shareholding of KHKPL.